Inscripta, a Boulder, CO and Pleasanton, CA-based gene-editing technology company, completed a $55.5m Series C funding.
Backers included Mérieux Développement and Paladin Capital Group and existing investors Venrock, Foresite, Spruce, and NanoDimension.
The company will use the funds to expand its research capabilities and strengthen its internal team of research experts.
Led by Kevin Ness, CEO, Inscripta is a gene-editing technology company that provides researchers with the tools they need for forward cell-engineering. These tools include a family of CRISPR enzymes (called MADzymes), custom nucleases for researchers and commercial partners, and a full suite of gene-editing tools (instruments, reagents, and software) that increase the speed and efficiency of multiplexed, precision gene editing.